These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 11212242

  • 1. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma.
    Valmori D, Dutoit V, Rubio-Godoy V, Chambaz C, Liénard D, Guillaume P, Romero P, Cerottini JC, Rimoldi D.
    Cancer Res; 2001 Jan 15; 61(2):509-12. PubMed ID: 11212242
    [Abstract] [Full Text] [Related]

  • 2. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
    Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, Liénard D, Speiser D, Guillaume P, Batard P, Cerottini JC, Romero P, Valmori D.
    Cancer Res; 2001 Aug 01; 61(15):5850-6. PubMed ID: 11479225
    [Abstract] [Full Text] [Related]

  • 3. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P.
    Cancer Res; 1997 Feb 15; 57(4):735-41. PubMed ID: 9044853
    [Abstract] [Full Text] [Related]

  • 4. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
    Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, Van Pel A.
    J Immunol; 1999 Jun 01; 162(11):6849-54. PubMed ID: 10352307
    [Abstract] [Full Text] [Related]

  • 5. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T, Tanaka F, Mori M, Takesako K, Sugimachi K, Akiyoshi T.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [Abstract] [Full Text] [Related]

  • 6. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.
    Vantomme V, Boël P, De Plaen E, Boon T, van der Bruggen P.
    Cancer Immun; 2003 Dec 10; 3():17. PubMed ID: 14664500
    [Abstract] [Full Text] [Related]

  • 7. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
    Lu J, Leng X, Peng J, Mou D, Pang X, Shang X, Chen W.
    Chin Med J (Engl); 2002 Jul 10; 115(7):1002-5. PubMed ID: 12150730
    [Abstract] [Full Text] [Related]

  • 8. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.
    Eur J Immunol; 2005 Apr 10; 35(4):1066-75. PubMed ID: 15756643
    [Abstract] [Full Text] [Related]

  • 9. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients.
    Hao X, Shao Y, Ren X, Liu H, Xu Q, Li H, Zhang P, An X, Ren B.
    J Cancer Res Clin Oncol; 2002 Sep 10; 128(9):507-15. PubMed ID: 12242516
    [Abstract] [Full Text] [Related]

  • 10. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.
    Valmori D, Pittet MJ, Vonarbourg C, Rimoldi D, Liénard D, Speiser D, Dunbar R, Cerundolo V, Cerottini JC, Romero P.
    Cancer Res; 1999 Aug 15; 59(16):4050-5. PubMed ID: 10463606
    [Abstract] [Full Text] [Related]

  • 11. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
    Akiyama Y, Maruyama K, Tai S, Komiyama M, Iizuka A, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.
    Anticancer Res; 2009 Feb 15; 29(2):647-55. PubMed ID: 19331215
    [Abstract] [Full Text] [Related]

  • 12. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
    Riley JP, Rosenberg SA, Parkhurst MR.
    J Immunother; 2001 Feb 15; 24(3):212-20. PubMed ID: 11394498
    [Abstract] [Full Text] [Related]

  • 13. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R, Ronteltap C, Heuveling M, Debets R, Bolhuis R.
    Gene Ther; 2005 Jan 15; 12(2):140-6. PubMed ID: 15496961
    [Abstract] [Full Text] [Related]

  • 14. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.
    Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B.
    Cancer Res; 1996 Jun 01; 56(11):2479-83. PubMed ID: 8653680
    [Abstract] [Full Text] [Related]

  • 15. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM, Zhang YF, Huang Y, Qu P, Ma B, Si SY, Li ZS, Li WX, Li X, Ge W, Hu PZ, Sui YF.
    Oncol Rep; 2008 Jul 01; 20(1):245-52. PubMed ID: 18575744
    [Abstract] [Full Text] [Related]

  • 16. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
    Baumgaertner P, Rufer N, Devevre E, Derre L, Rimoldi D, Geldhof C, Voelter V, Liénard D, Romero P, Speiser DE.
    Cancer Res; 2006 Feb 15; 66(4):1912-6. PubMed ID: 16488988
    [Abstract] [Full Text] [Related]

  • 17. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
    Kobayashi H, Song Y, Hoon DS, Appella E, Celis E.
    Cancer Res; 2001 Jun 15; 61(12):4773-8. PubMed ID: 11406551
    [Abstract] [Full Text] [Related]

  • 18. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.
    Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie PG.
    Cancer Res; 2008 May 15; 68(10):3931-40. PubMed ID: 18483279
    [Abstract] [Full Text] [Related]

  • 19. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
    van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T.
    J Clin Oncol; 2005 Dec 10; 23(35):9008-21. PubMed ID: 16061912
    [Abstract] [Full Text] [Related]

  • 20. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D, Speiser D.
    Cancer Res; 2003 Sep 01; 63(17):5601-6. PubMed ID: 14500401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.